TBC1D30: A Potential Drug Target and Biomarker for KIAA0984 (G23329)

Target Name: TBC1D30

NCBI ID: G23329

TBC1D30

TBC1D30: A Potential Drug Target and Biomarker for KIAA0984

Abstract:

TBC1D30, a protein encoded by the gene KIAA0984, has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer. Its unique structure, localization, and interactions with other proteins make it an attractive target for small molecule inhibitors . This review summarizes the current understanding of TBC1D30, its potential drug targets, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:

The protein encoded by the gene KIAA0984, also known as TBC1D30, is a member of the superfamily of cytoskeletal proteins, which are involved in cell structure and dynamics. Its unique structure, localization, and interactions with other proteins have made it an attractive target for small molecule inhibitors. In recent years, researchers have discovered interactions between TBC1D30 and drugs in multiple disease areas, indicating its potential as a drug target and biomarker.

1. Structure and function of TBC1D30

TBC1D30 is a protein composed of 21 amino acids with a molecular weight of 25 kDa (1.95 Molar Mass). It is located in the cytoplasm and interacts with other proteins, such as histones LSP1, SPOP, etc.

The secondary structure of TBC1D30 is mainly composed of 伪-helices and 尾-sheets. Its 伪-helices mainly appear at the N-terminus, while 尾-sheets mainly appear at the C-terminus. In addition, the C-terminus of TBC1D30 contains a free 伪-helical structure, which allows it to have a certain degree of variability and can adapt to various intracellular environments.

The biological functions of TBC1D30 mainly involve processes such as cell cycle, spindle formation, cell division and apoptosis. It plays an important role in mitosis during the cell cycle and can influence spindle formation and stability. In addition, TBC1D30 is also involved in apoptosis and is an important player in the apoptosis signal transduction pathway.

2. Drug targets of TBC1D30

As a protein, TBC1D30 has multiple drug targets. Currently, researchers are focusing on TBC1D30's interaction with drugs and its potential as a drug target.

1. Interactions with anti-tumor drugs

TBC1D30 is one of the focuses of anti-tumor drug research. Studies have found that TBC1D30 combined with anti-tumor drugs such as cisplatin and paclitaxel can significantly inhibit its cell growth and spindle formation, thus affecting the development of tumors. In addition, TBC1D30 can also affect tumor cell apoptosis by regulating cell cycle and spindle formation.

2. Interactions with immune drugs

TBC1D30 also plays an important role in immune cells. Studies have shown that TBC1D30 can regulate the activity and differentiation of immune cells, thereby affecting the quality and effect of immune responses. In addition, TBC1D30 can also affect the killing effect of immune cells on tumor cells.

3. Interactions with neuroprotective drugs

TBC1D30 also plays an important role in neuroprotection. Studies have shown that TBC1D30 can regulate the proliferation and apoptosis of nerve cells, thereby affecting the recovery and protection of nerve function.

3. Biomarkers of TBC1D30

TBC1D30 has a potential biomarker role in disease diagnosis and treatment. Its expression level can reflect the size, growth rate and invasiveness of tumors, and can also be used to evaluate the efficacy and resistance of anti-tumor drugs. In addition, TBC1D30 can also be used as a potential biomarker to predict the survival of cancer patients.

4. Conclusion

TBC1D30 is a protein with multiple biological functions and drug targets, and can be used as a potential drug target or biomarker to treat a variety of diseases, including tumors, immune diseases, and neurological diseases. Currently, researchers are conducting in-depth studies on the pharmacological and biological functions of TBC1D30 in order to develop promising drugs.

Protein Name: TBC1 Domain Family Member 30

Functions: GTPase-activating protein (GAP) with broad specificity. Acts as a GAP for RAB3A. Also exhibits significant GAP activity toward RAB22A, RAB27A, and RAB35 in vitro

The "TBC1D30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets